Malignant neoplasm of breast
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our findings demonstrated suggestive associations of AEI polymorphisms with breast cancer risk (MUC16 rs2591592 and SLAMF1 rs1061217) and prognosis (ZNF331 rs8109631 and CHRAC1 rs10216653).
|
27128794 |
2017 |
Malignant neoplasm of breast
|
0.310 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Eczema
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Measles
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, limited information is available about the CD150 expression and relative susceptibility to MV infection of B-cell subsets.
|
29437964 |
2018 |
Measles
|
0.100 |
Biomarker
|
disease |
BEFREE |
High pathogenicity of wild-type measles virus infection in CD150 (SLAM) transgenic mice.
|
16775330 |
2006 |
Measles
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dimers of MV-specific peptides derived from the C-terminal heptad repeat region of the MV fusion protein, conjugated to cholesterol, efficiently protect SLAM transgenic mice from fatal MV infection.
|
24109233 |
2013 |
Measles
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD150 transgenic (Tg) mice, which express human CD150, an entry receptor for MV, with the disrupting IFNR gene (Ifnar(-/-)), are susceptible to MV and serve as a model for MV infection.
|
24078691 |
2013 |
Measles
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the natural host of MV is human, mouse models expressing MV entry receptors (human CD46, CD150) and disrupting the interferon (IFN) pathways work for investigating immune responses during early MV infection in vivo.
|
24905956 |
2014 |
Measles
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Measles virus infects and suppresses proliferation of T lymphocytes from transgenic mice bearing human signaling lymphocytic activation molecule.
|
12610126 |
2003 |
Measles
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Measles virus interacts with human SLAM receptor on dendritic cells to cause immunosuppression.
|
15193925 |
2004 |
Measles
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To identify cells supporting primary MV infection, we took advantage of mice expressing the MV receptor human signaling lymphocyte activation molecule (SLAM, CD150) with human-like tissue specificity.
|
20042501 |
2010 |
Measles
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic variation in key innate pathogen recognition receptors, such as the measles cell entry receptors CD46 and SLAM, measles attachment receptor DC-SIGN, the antiviral toll-like receptors (TLR)3, TLR7 and TLR8, and the cytosolic antiviral receptor RIG-I, may significantly affect measles IgG antibody responses.
|
22871352 |
2012 |
Measles
|
0.100 |
Biomarker
|
disease |
BEFREE |
The measles virus (MV) interacts with two known cellular receptors: CD46 and SLAM.
|
22086389 |
2011 |
Measles
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have previously shown that attenuated vaccine strains of measles virus have potent antitumor activity against gliomas, and identified H protein mutations, which ablate recognition of the natural measles virus receptors CD46 and SLAM.
|
17178881 |
2006 |
Measles
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using organotypic brain cultures (OBC) from wild-type and IFNAR-knockout (IFNAR<sup>KO</sup>) transgenic mice ubiquitously expressing the human SLAM (CD150) receptor, the heterogeneity of the permissiveness of different CNS cell types to MeV infection was characterized.
|
31019048 |
2019 |
X-Linked Lymphoproliferative Disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The molecular basis of XLP has been attributed to mutations of signaling lymphocytic activation molecule-associated protein, an intracellular molecule known to associate with the lymphocyte-activating surface receptors SLAM and 2B4.
|
11034354 |
2000 |
X-Linked Lymphoproliferative Disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, we will discuss the role of SLAM receptors and their adapters in T cell function, and we will examine the role of these receptors and their adapters in X-linked lymphoproliferative disease and their contribution to disease susceptibility in systemic lupus erythematosus.
|
20146065 |
2010 |
X-Linked Lymphoproliferative Disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
SAP, the product of the gene mutated in X-linked lymphoproliferative syndrome (XLP), consists of a single SH2 domain that has been shown to bind the cytoplasmic tail of the lymphocyte coreceptor SLAM.
|
10549287 |
1999 |
X-Linked Lymphoproliferative Disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The SH2 domain protein SAP/SH2D1A, encoded by the X-linked lymphoproliferative (XLP) syndrome gene, associates with the hematopoietic cell surface receptor SLAM in a phosphorylation-independent manner.
|
11823424 |
2002 |
X-Linked Lymphoproliferative Disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease.
|
14523387 |
2003 |
X-Linked Lymphoproliferative Disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
SAP (SLAM-associated protein) was identified in 1998 as an adaptor molecule involved in the intracellular signaling pathways elicited through the cell surface receptor SLAM and as the protein defective in the human immunodeficiency X-linked lymphoproliferative disease (XLP).
|
17201683 |
2007 |
X-Linked Lymphoproliferative Disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further studies of SAP and the SLAM family receptors will provide insights into XLP and elucidate the signaling events regulating lymphocyte ontogeny and function.
|
15661030 |
2005 |
X-Linked Lymphoproliferative Disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Being a partner of SH2D1A and having a key role in proliferation and differentiation of the T- and B-lymphocytes, SLAM was considered as a candidate gene for patients who manifest symptoms of X-linked lymphoproliferative disease but who have no mutations in SH2D1A.
|
12629654 |
2003 |
X-Linked Lymphoproliferative Disorder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The molecular basis of X-linked lymphoproliferative (XLP) disease has been attributed to mutations in the signaling lymphocytic activation molecule-associated protein (SAP), an src homology 2 domain-containing intracellular signaling molecule known to interact with the lymphocyte-activating surface receptors signaling lymphocytic activation molecule and 2B4.
|
11509608 |
2001 |
X-Linked Lymphoproliferative Disorder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Signaling lymphocytic activation molecule (SLAM)-associated protein (SAP) mutations in X-linked lymphoproliferative disease (XLP) lead to defective NKT cell development and impaired humoral immunity.
|
28049627 |
2017 |